Drugs / Recombinant human CTLA-4-FC fusion protein
Recombinant human CTLA-4-FC fusion protein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05256719 | Sep 2021 → Dec 2025 | — | Beijing VDJBio Co., LTD. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human CTLA-4-FC fusion protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05256719 ↗ |
| Modality | Protein / enzyme biologic | “recombinant humanized CTLA-4-FC fusion protein injection” NCT05256719 ↗ |
| Route | Intravenous | “Subjects are randomly assigned to receive intravenous administration of the test drug or placebo.” NCT05256719 ↗ |